"Like many of my colleagues, it is my personal experience with cancer that drives my passion to change the way we diagnose and treat this complex disease that touches so many lives. As we gain greater understanding of the biology of cancer, we have an opportunity and a responsibility to develop tools that arm both physicians and patients with personalized genomic information to individualize the treatment of a patient´s disease. With the advent of biologics and new targeted therapeutics, the menu of treatment options for patients with cancer is growing. It is our mission to develop tests that employ the biology of an individual´s specific tumor to help physicians select appropriate treatments from this expanding menu. We are entering an era where we have the information and means to transform "one-size-fits-all" medicine to a world where treatment is truly personalized. We remain steadfast in our mission to provide cancer patients with access to information that can empower them to better manage their disease. Oncotype DX is the beginning. Our commitment is to set no limit on the end."
Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that personalize and optimize treatment decisions. Kim has served as Genomic Health's Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®1, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Kim currently serves on the boards of the Personalized Medicine Coalition (PMC), the American Clinical Laboratory Association (ACLA), MyoKardia and Kiniksa Pharmaceuticals. Kim is also the President of The Coalition for 21st Century Medicine. Kim's contributions to the science and commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 and one of the Forever Influential Women in the Bay Area from by the San Francisco Business Times. She was also named Woman of the Year by Women Health Care Executives in 2008, received the Ferolyn Powell Leadership Award from MedTechWomen in 2016, and received the Salute to Excellence Award from the American Liver Foundation in 2017. Kim holds a Bachelor of Arts degree in Business from Michigan State University.

1 Herceptin is a registered trademark of Genentech, Inc.
Oncotype DX My Colon Cancer Coach